A Phase 2 Study of Stem-Cell-Mobilization in Subjects With Diabetic Neuropathy Receiving SB-509.

Trial Profile

A Phase 2 Study of Stem-Cell-Mobilization in Subjects With Diabetic Neuropathy Receiving SB-509.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2017

At a glance

  • Drugs SB 509 (Primary)
  • Indications Diabetic neuropathies
  • Focus Pharmacodynamics
  • Sponsors Sangamo BioSciences
  • Most Recent Events

    • 03 Mar 2010 Actual number of patients (23) added as reported by ClinicalTrials.gov.
    • 03 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Sep 2008 Status changed from recruiting to active, no longer recruiting according to CLinialtrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top